logo
Sign in

Amicus Therapeutics

Princeton, NJ · Biotech · Acquired

Small-molecule and enzyme replacement therapeutics for rare genetic diseases

Claim this profile

Follows are private to you and power your alerts

Updated · amicusrx.com

Sector
Biotech
Headquarters
Princeton, NJ
Latest Form D
$30M, Oct 2023
Total capital
$314M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$314M
7 Form D · last Oct 2023
36 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
20
20 pending · first 2024
Rank in peer group#13 of 1449

Capital timeline

2010201220142016201820202022FEDERAL ↑EQUITY ↓Cumulative $314M3rd Form D$15M6th Form D$200M
2010201420182022FEDERAL ↑EQUITY ↓Cumulative $314M6th Form D$200M

Latest events

  • Private capital raisedForm D · SEC · 7th filing$30M
  • Private capital raisedForm D · SEC · 6th filing$200M
  • Private capital raisedForm D · SEC · 5th filing$4.7M
  • Private capital raisedForm D · SEC · 4th filing$15M
  • Private capital raisedForm D · SEC · 3rd filing$15M
  • Private capital raisedForm D · SEC · 2nd filing$18.6M
  • Private capital raisedForm D · SEC · 1st filing$31.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#13 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Alexander E BarkasDirectorNamed in SEC Form D filings
  • Bradley L. CampbellExecutive OfficerNamed in SEC Form D filings
  • Burke W. WhitmanDirectorNamed in SEC Form D filings
  • Craig A WheelerDirectorNamed in SEC Form D filings
  • Daphne D. QuimiExecutive OfficerNamed in SEC Form D filings
  • David M. ClarkExecutive OfficerNamed in SEC Form D filings
Show all 41 people
  • David J. LockhartExecutive OfficerNamed in SEC Form D filings
  • Donald J HaydenDirectorNamed in SEC Form D filings
  • Donald J. Hayden, Jr.DirectorNamed in SEC Form D filings
  • Eiry L. RobertsDirectorNamed in SEC Form D filings
  • Eiry W Roberts, M.D.DirectorNamed in SEC Form D filings
  • Ellen S. RosenbergExecutive OfficerNamed in SEC Form D filings
  • Enrique R. DiloneExecutive OfficerNamed in SEC Form D filings
  • Geoffrey P GilmoreExecutive OfficerNamed in SEC Form D filings
  • Glenn P. SblendorioDirectorNamed in SEC Form D filings
  • Glen G. SblendorioDirectorNamed in SEC Form D filings
  • James J. BarrettDirectorNamed in SEC Form D filings
  • James N TopperDirectorNamed in SEC Form D filings
  • Jayne W. GerskowitzExecutive OfficerNamed in SEC Form D filings
  • Jeffrey P. CastelliExecutive OfficerNamed in SEC Form D filings
  • Jeffrey P. Castelli, Ph.D.Executive OfficerNamed in SEC Form D filings
  • Joan C. WinterbottomExecutive OfficerNamed in SEC Form D filings
  • John F CrowleyExecutive Officer, DirectorNamed in SEC Form D filings
  • John R. KirkExecutive OfficerNamed in SEC Form D filings
  • Kenneth W. PeistExecutive OfficerNamed in SEC Form D filings
  • Ken R ValenzanoExecutive OfficerNamed in SEC Form D filings
  • Lynn D. BleilDirectorNamed in SEC Form D filings
  • Margaret G. McGlynnDirectorNamed in SEC Form D filings
  • Matthew R PattersonExecutive OfficerNamed in SEC Form D filings
  • Michael A. KellyDirectorNamed in SEC Form D filings
  • Michael G. RaabDirectorNamed in SEC Form D filings
  • P Sherrill NeffDirectorNamed in SEC Form D filings
  • Pol F BoudesExecutive OfficerNamed in SEC Form D filings
  • Robert W. EssnerDirectorNamed in SEC Form D filings
  • Robert W. WinklerExecutive OfficerNamed in SEC Form D filings
  • Samantha M. ProutExecutive OfficerNamed in SEC Form D filings
  • Simon HarfordExecutive OfficerNamed in SEC Form D filings
  • Sol J. BarerDirectorNamed in SEC Form D filings
  • S Nicole SchaefferExecutive OfficerNamed in SEC Form D filings
  • Ted W. LoveDirectorNamed in SEC Form D filings
  • William D. Baird, IIIExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 20 granted of 40
Show all 40 patent records

Related companies, and why

  • REGENXBIO Inc.Similar federal contract value in Biotech · null in contracts
  • RallybioSimilar federal contract value in Biotech · null in contracts
  • Autobahn TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • ReCode TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • NuPeak Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • D3 BioSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .